Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "Targeting PI3K/AKT/mTOR Signaling Pathway in Cancer"
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".
Deadline for manuscript submissions: closed (20 March 2023) | Viewed by 6307
Special Issue Editors
Interests: PI3K/AKT/mTOR; oxidative stress; breast cancer; burns; colorectal cancer; PLGA nanoparticles; platelet rich plasma
Interests: dental biochemistry; oxidative stress in systemic and oral diseases; salivary biomarkers; AKT/mTOR signaling pathway; molecular and biochemical aspects in burns
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
The phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signaling pathway regulates the cell proliferation, growth, survival, invasion, migration, glucose metabolism, apoptosis, and motility of cells. Growth factors, hormones, mitogens, cytokines, and chemokines activate this molecular pathway after binding to receptor tyrosine kinases (RTKs) or G protein-coupled receptors (GPCP). PI3K/AKT/mTOR dysregulation is frequently associated with genetic/epigenetic alterations in a wide variety of human cancers, including breast, skin, lung, gastric, colorectal, renal, ovarian, oral, and prostate. The inactivation of phosphatase and tensin homolog (PTEN) and/or activation of PIK3CA and RTKs mutations are frequently reported in cancer, contributing to tumor growth and survival. Thus, inhibitors have been developed to block the key players, PI3K/ AKT/mTOR, some of them already approved by the FDA, with promising results in clinical trials. PI3K/AKT/mTOR pathway inhibition may be a new method of improving cancer patients’ survival rate.
In this Special Issue, emphasis will be put on the molecular facets of the relationship between PI3K/AKT/mTOR and cancer. Original research (molecular mechanisms and preclinical) and review articles are welcome.
Dr. Daniela Miricescu
Prof. Dr. Maria Greabu
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- growth factors
- signaling pathway dysregulation
- PI3K/AKT/mTOR mutations
- clinical inhibitors